Seeking Alpha

AstraZeneca (AZN +0.3%) plans to carry out a worldwide study of its Brilinta heart treatment...

AstraZeneca (AZN +0.3%) plans to carry out a worldwide study of its Brilinta heart treatment using 11,500 people with peripheral artery disease. The trial will compare Brilinta, which is approved for acute-coronary syndrome patients, against Plavix, which is marketed by Bristol-Myers Squibb (BMY) and Sanofi (SNY).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs